Loading...
FGEN logo

FibroGen, Inc.NasdaqGS:FGEN Stock Report

Market Cap US$45.0m
Share Price
US$11.01
My Fair Value
n/a
1Y35.3%
7D-1.0%
Portfolio Value
​
View

FibroGen, Inc.

NasdaqGS:FGEN Stock Report

Market Cap: US$45.0m

FibroGen (FGEN) Stock Overview

A biopharmaceutical company, discovers, develops, and commercializes therapeutics to treat serious unmet medical needs. More details

FGEN fundamental analysis
Snowflake Score
Valuation2/6
Future Growth0/6
Past Performance0/6
Financial Health0/6
Dividends0/6

Rewards

Earnings have grown 5.2% per year over the past 5 years

Risk Analysis

Has less than 1 year of cash runway

Negative shareholders equity

Earnings are forecast to decline by an average of 0.2% per year for the next 3 years

Currently unprofitable and not forecast to become profitable over the next 3 years

+ 1 more risk

FGEN Community Fair Values

Create Narrative

See what others think this stock is worth. Follow their fair value or set your own to get alerts.

FGEN logo
FibroGen

Clinical Trials And Regulatory Advances Will Open US Markets

Key Takeaways Advancing precision oncology and rare disease treatments positions the company for future revenue growth and strong market opportunities in underserved populations. Liquidity improvements and strategic pipeline diversification reduce financial risk while enhancing long-term earnings stability and optionality.
View narrative
US$43
FV
74.4% undervalued intrinsic discount
-3.88%
Revenue growth p.a.
0users have liked this narrative
0users have commented on this narrative
1users have followed this narrative
View Stock Community

FibroGen, Inc. Competitors

Price History & Performance

Summary of share price highs, lows and changes for FibroGen
Historical stock prices
Current Share PriceUS$11.01
52 Week HighUS$21.94
52 Week LowUS$4.50
Beta0.77
1 Month Change-6.14%
3 Month Change59.33%
1 Year Change35.34%
3 Year Change-97.27%
5 Year Change-98.92%
Change since IPO-98.00%

Recent News & Updates

Recent updates

User avatar

Simplifying Operations And Advancing FG-3246 Will Secure Future Success

Strategic cost reductions and the sale of FibroGen China enhance financial stability, extending cash runway and potentially boosting overall financial performance.

Investors Don't See Light At End Of FibroGen, Inc.'s (NASDAQ:FGEN) Tunnel And Push Stock Down 26%

Apr 08
Investors Don't See Light At End Of FibroGen, Inc.'s (NASDAQ:FGEN) Tunnel And Push Stock Down 26%

There's No Escaping FibroGen, Inc.'s (NASDAQ:FGEN) Muted Revenues Despite A 46% Share Price Rise

Feb 21
There's No Escaping FibroGen, Inc.'s (NASDAQ:FGEN) Muted Revenues Despite A 46% Share Price Rise

There's No Escaping FibroGen, Inc.'s (NASDAQ:FGEN) Muted Revenues Despite A 26% Share Price Rise

Dec 25
There's No Escaping FibroGen, Inc.'s (NASDAQ:FGEN) Muted Revenues Despite A 26% Share Price Rise

Little Excitement Around FibroGen, Inc.'s (NASDAQ:FGEN) Revenues As Shares Take 26% Pounding

Oct 29
Little Excitement Around FibroGen, Inc.'s (NASDAQ:FGEN) Revenues As Shares Take 26% Pounding

The Market Doesn't Like What It Sees From FibroGen, Inc.'s (NASDAQ:FGEN) Revenues Yet As Shares Tumble 65%

Aug 19
The Market Doesn't Like What It Sees From FibroGen, Inc.'s (NASDAQ:FGEN) Revenues Yet As Shares Tumble 65%

Little Excitement Around FibroGen, Inc.'s (NASDAQ:FGEN) Revenues As Shares Take 44% Pounding

Jul 04
Little Excitement Around FibroGen, Inc.'s (NASDAQ:FGEN) Revenues As Shares Take 44% Pounding

FibroGen: Two New In-Licensed Oncology Drugs To Carry It Forward

Jun 06

Pamrevlumab And Roxadustat: Evaluating FibroGen's Future Amid Financial Strains

May 28

Benign Growth For FibroGen, Inc. (NASDAQ:FGEN) Underpins Stock's 28% Plummet

May 07
Benign Growth For FibroGen, Inc. (NASDAQ:FGEN) Underpins Stock's 28% Plummet

FibroGen, Inc.'s (NASDAQ:FGEN) Share Price Boosted 35% But Its Business Prospects Need A Lift Too

Mar 22
FibroGen, Inc.'s (NASDAQ:FGEN) Share Price Boosted 35% But Its Business Prospects Need A Lift Too

There's No Escaping FibroGen, Inc.'s (NASDAQ:FGEN) Muted Revenues Despite A 148% Share Price Rise

Feb 05
There's No Escaping FibroGen, Inc.'s (NASDAQ:FGEN) Muted Revenues Despite A 148% Share Price Rise

FibroGen, Inc. (NASDAQ:FGEN) Held Back By Insufficient Growth Even After Shares Climb 42%

Dec 22
FibroGen, Inc. (NASDAQ:FGEN) Held Back By Insufficient Growth Even After Shares Climb 42%

A Look At The Intrinsic Value Of FibroGen, Inc. (NASDAQ:FGEN)

Nov 24
A Look At The Intrinsic Value Of FibroGen, Inc. (NASDAQ:FGEN)

Revenues Not Telling The Story For FibroGen, Inc. (NASDAQ:FGEN)

Apr 18
Revenues Not Telling The Story For FibroGen, Inc. (NASDAQ:FGEN)

Health Check: How Prudently Does FibroGen (NASDAQ:FGEN) Use Debt?

Feb 13
Health Check: How Prudently Does FibroGen (NASDAQ:FGEN) Use Debt?

The FibroGen, Inc. (NASDAQ:FGEN) Analysts Have Been Trimming Their Sales Forecasts

Nov 12
The FibroGen, Inc. (NASDAQ:FGEN) Analysts Have Been Trimming Their Sales Forecasts

Health Check: How Prudently Does FibroGen (NASDAQ:FGEN) Use Debt?

Oct 09
Health Check: How Prudently Does FibroGen (NASDAQ:FGEN) Use Debt?

FibroGen completes patient enrollment for Roxadustat to treat anemia in patients

Aug 26

Shareholder Returns

FGENUS BiotechsUS Market
7D-1.0%2.8%-0.2%
1Y35.3%4.0%20.3%

Return vs Industry: FGEN exceeded the US Biotechs industry which returned 4% over the past year.

Return vs Market: FGEN exceeded the US Market which returned 20.3% over the past year.

Price Volatility

Is FGEN's price volatile compared to industry and market?
FGEN volatility
FGEN Average Weekly Movement10.7%
Biotechs Industry Average Movement10.7%
Market Average Movement6.4%
10% most volatile stocks in US Market17.4%
10% least volatile stocks in US Market3.0%

Stable Share Price: FGEN has not had significant price volatility in the past 3 months compared to the US market.

Volatility Over Time: FGEN's weekly volatility (11%) has been stable over the past year.

About the Company

FoundedEmployeesCEOWebsite
1993225Thane Wettigwww.fibrogen.com

FibroGen, Inc., a biopharmaceutical company, discovers, develops, and commercializes therapeutics to treat serious unmet medical needs. Its lead product candidates are Roxadustat, a small molecule inhibitor of hypoxia-inducible factor prolyl hydroxylase activity, which has completed Phase III clinical development for the treatment of anemia in chronic kidney disease in China, Europe, Japan, and other countries, as well as in Phase III clinical development for anemia related with myelodysplastic syndromes. Its pipeline products include FG-3165 and FG-3175, an anti-GAL-9 antibody for treatment of solid tumors.

FibroGen, Inc. Fundamentals Summary

How do FibroGen's earnings and revenue compare to its market cap?
FGEN fundamental statistics
Market capUS$44.97m
Earnings (TTM)-US$87.41m
Revenue (TTM)US$7.35m
6.1x
P/S Ratio
-0.5x
P/E Ratio

Is FGEN overvalued?

See Fair Value and valuation analysis

Earnings & Revenue

Key profitability statistics from the latest earnings report (TTM)
FGEN income statement (TTM)
RevenueUS$7.35m
Cost of RevenueUS$36.30m
Gross Profit-US$28.95m
Other ExpensesUS$58.45m
Earnings-US$87.41m

Last Reported Earnings

Jun 30, 2025

Next Earnings Date

n/a

Earnings per share (EPS)-21.61
Gross Margin-394.13%
Net Profit Margin-1,189.84%
Debt/Equity Ratio-51.4%

How did FGEN perform over the long term?

See historical performance and comparison

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2025/11/03 00:05
End of Day Share Price 2025/11/03 00:00
Earnings2025/06/30
Annual Earnings2024/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* Example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.

Analyst Sources

FibroGen, Inc. is covered by 13 analysts. 2 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution
Jason Matthew GerberryBofA Global Research
Matthew KellerH.C. Wainwright & Co.
Xiaodong ZhangH.C. Wainwright & Co.